Aromatase inhibitors and arthralgias: a new frontier in symptom management for breast cancer survivors. Clinical Oncology

摘要

Aromatase inhibitors (AIs) have become widely used as adjuvant therapy for postmenopausal women with hormone receptor-positive breast cancer. Although the optimal schedule and duration remain unclear, current guidelines endorse the inclusion of AI treatment at some point during adjuvant therapy for most postmenopausal women with estrogen receptor-positive breast cancer. Because of the incidence and demographics of breast cancer, hundreds of thousands of breast cancer patients throughout the world will start AI therapy each year.